Viridian Therapeutics is a high-risk, single-asset biotech trading at $16.30 with 96% revenue growth but critically weak business quality (quality score 1.6), heavy cash burn at negative 257% free cash flow relative to revenue, and 14% short interest — the stock offers high asymmetry upside to $30.54 only if it can close its quality gap and sustain clinical momentum.
Thesis pillars
- Cash Burn Pipeline Concentration→Stable
- Analyst Sentiment Upside↓Deteriorating
- Earnings Beat Trajectory→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 26, 2026· older than 90 days
Viridian Therapeutics, Inc. (VRDN) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $25.15: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 2.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality.
Viridian Therapeutics is a biopharmaceutical company developing antibody therapies for autoimmune and rare diseases, with veligrotug, an IV anti-IGF-1R antibody for thyroid eye disease, as its lead candidate. The company submitted a BLA for veligrotug in October 2025 with a... Read more
Sell if holding. Engine safety override at $25.15: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 2.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.9/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Viridian Therapeutics, Inc.
About Viridian Therapeutics, Inc.
Viridian Therapeutics has no approved products, making its Phase 3 veligrotug program the sole near-term value inflection — the FDA granted Priority Review on a veligrotug BLA accepted in December 2025, with a PDUFA target action date of June 30, 2026, and the company additionally submitted an MAA to the EMA in January 2026. Cash and marketable securities stood at $874.7 million at December 31, 2025, against a net loss of $342.6 million for the year and an accumulated deficit of $1,338.5 million.
Viridian generates no revenue from product sales and has financed operations through equity, debt, and collaboration agreements. The company holds worldwide commercialization rights to veligrotug and elegrobart, excluding Japan and the greater China area, under arrangements that include royalty and milestone obligations. Veligrotug competes directly with Tepezza (teprotumumab), marketed by Amgen, which posted approximately $1.9 billion in 2025 net sales at an estimated list price of $525,000 per course; veligrotug's five-dose IV regimen features fewer infusions versus teprotumumab's eight-dose regimen. Elegrobart, a subcutaneous IGF-1R antibody with a 40–50-day half-life, is in Phase 3 pivotal studies REVEAL-1 and REVEAL-2, which completed enrollment in September 2025, with topline data expected in Q1 and Q2 2026, respectively. A TSHR inhibitor program IND is planned for Q4 2026. Manufacturing relies on CDMOs and external suppliers subject to FDA cGMP inspection rights.
Show full overview
The regulatory pathway for veligrotug rests on the THRIVE and THRIVE-2 Phase 3 trials plus a 300-patient safety database; however, the 10-K warns the FDA may require additional patients or steps beyond what the company has planned. Elegrobart's eventual BLA also depends on demonstrating bioequivalence between the vial formulation used in REVEAL-1/REVEAL-2 and the planned autoinjector — a risk the 10-K flags as potentially delaying or denying approval if bioequivalence is not shown. In May 2026, Viridian disclosed via Form 8-K the voluntary termination of the Hercules Capital term loan following a $55.1 million prepayment, removing financial covenants that had constrained capital deployment ahead of a potential commercial launch.
See also: Healthcare · Biotechnology
From Viridian Therapeutics, Inc.'s most recent 10-K filing, extracted June 16, 2026.
Recent developments
updated Oct 30, 2026Recent Developments — Viridian Therapeutics, Inc.
Latest news
- NEWS Viridian Metals Inc. Announces Up to $5 Million Private Placement — fiscal.ai Oct 30, 2026 neutral
- NEWS Viridian Metals Inc. Reports Assay Results from Kraken Project Step-Out Drilling — fiscal.ai Oct 23, 2026 neutral
- NEWS Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026 — fiscal.ai Oct 20, 2026
- NEWS Roche Secures FDA Approval for First At-Home Thyroid Eye Disease Therapy — benzinga Oct 16, 2026 positive
- NEWS RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $38 — benzinga Sep 22, 2026 positive
Latest item Oct 30, 2026 · Generated 2026-11-04T12:04:37Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineveligrotug10-K Item 1: 'BLA for veligrotug to the FDA in October 2025, which was accepted for filing and granted Priority Review in December 2025 ... target action date of June 30, 2026'
Material Events(8-K, last 90d)
- 2026-05-28Item 1.02MEDIUMOn May 27, 2026, Viridian Therapeutics voluntarily prepaid ~$55.1 million to Hercules Capital, fully terminating the April 2022 Loan and Security Agreement ($50M drawn of $300M max, floating rate capped at 9.45%). All obligations discharged in full.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $25.15: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 2.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $23.39. Score 4.9/10, moderate confidence.
Analyst target: $32.58 (+29.5% upside). Prior stop was $23.39. Stop-loss: $23.39.
Concentration risk — Pipeline: veligrotug; Quality below floor (1.8 < 4.0); Value-trap signals (4/5): Margin compression (op margin -81.6%), High leverage (D/E 1.7), Material insider selling (3 sells, 0.03% of cap)….
Viridian Therapeutics, Inc. trades at a P/E of N/A (forward -9.3). TrendMatrix value score: 5.4/10. Verdict: Sell.
23 analysts rate VRDN, with a consensus score of 4.3/5. 15 analysts publish price targets averaging $36.
What does Viridian Therapeutics, Inc. do?Viridian Therapeutics is a biopharmaceutical company developing antibody therapies for autoimmune and rare diseases,...
Viridian Therapeutics is a biopharmaceutical company developing antibody therapies for autoimmune and rare diseases, with veligrotug, an IV anti-IGF-1R antibody for thyroid eye disease, as its lead candidate. The company submitted a BLA for veligrotug in October 2025 with a PDUFA date of June 30, 2026; it has no approved products or product revenue, with $874.7 million cash at December 31, 2025.